Literature DB >> 3694177

The sequence of the M RNA of an isolate of La Crosse virus.

L J Grady1, M L Sanders, W P Campbell.   

Abstract

The middle-size (M) genomic RNA of a New York State, U.S.A. isolate of La Crosse (LAC) virus has been cloned by a random priming procedure and its nucleotide sequence determined by the dideoxy method. The RNA was found to be 4526 nucleotides in length and to have a base composition of 34.2% U, 27.8% A, 20.6% C and 17.4% G. There is a single, long open reading frame in the viral complementary RNA that contains sufficient information to code for a protein of 1441 amino acids. In these respects, as in many others, the LAC virus M RNA and its encoded protein were very similar, if not identical, to those previously reported by other investigators for the closely related snowshoe hare virus. The M RNAs of the two viruses show 79% nucleotide sequence homology and 89% homology in the amino acid sequence of their encoded proteins. Several algorithms for predicting surface residues, as well as the Chou-Fasman rules for predicting secondary structure, were used to compare the LAC virus and snowshoe hare virus M gene proteins. These analyses identified 39 sites on the proteins as those most likely to be linear antigenic determinants that might contribute to the differences between the two viruses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3694177     DOI: 10.1099/0022-1317-68-12-3057

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Anti-mRNAs in La Crosse bunyavirus-infected cells.

Authors:  D Hacker; S Rochat; D Kolakofsky
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  The translational requirement for complete La Crosse virus mRNA synthesis is cell-type dependent.

Authors:  R Raju; L Raju; D Kolakofsky
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  The ends of La Crosse virus genome and antigenome RNAs within nucleocapsids are base paired.

Authors:  R Raju; D Kolakofsky
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Sequence analysis of the medium (M) segment of Cache Valley virus, with comparison to other Bunyaviridae.

Authors:  C L Brockus; P R Grimstad
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Genomic and phylogenetic characterization of Leanyer virus, a novel orthobunyavirus isolated in northern Australia.

Authors:  Nazir Savji; Gustavo Palacios; Amelia Travassos da Rosa; Stephen Hutchison; Christopher Celone; Jeffrey Hui; Thomas Briese; Charles H Calisher; Robert B Tesh; W Ian Lipkin
Journal:  J Gen Virol       Date:  2011-03-14       Impact factor: 3.891

6.  Identification of super-infected Aedes triseriatus mosquitoes collected as eggs from the field and partial characterization of the infecting La Crosse viruses.

Authors:  Sara M Reese; Eric C Mossel; Meaghan K Beaty; Eric T Beck; Dave Geske; Carol D Blair; Barry J Beaty; William C Black
Journal:  Virol J       Date:  2010-04-22       Impact factor: 4.099

7.  Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes).

Authors:  Courtney E Garry; Robert F Garry
Journal:  Theor Biol Med Model       Date:  2004-11-15       Impact factor: 2.432

8.  Comparative sequence analyses of La Crosse virus strain isolated from patient with fatal encephalitis, Tennessee, USA.

Authors:  Amy J Lambert; Rebecca Trout Fryxell; Kimberly Freyman; Armando Ulloa; Jason O Velez; Dave Paulsen; Robert S Lanciotti; Abelardo Moncayo
Journal:  Emerg Infect Dis       Date:  2015-05       Impact factor: 6.883

9.  Genetic and Phylogenetic Characterization of Tataguine and Witwatersrand Viruses and Other Orthobunyaviruses of the Anopheles A, Capim, Guamá, Koongol, Mapputta, Tete, and Turlock Serogroups.

Authors:  Alexey M Shchetinin; Dmitry K Lvov; Petr G Deriabin; Andrey G Botikov; Asya K Gitelman; Jens H Kuhn; Sergey V Alkhovsky
Journal:  Viruses       Date:  2015-11-23       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.